GSK’s Nucala secures NICE COPD endorsement - Pharmaceutical Technology

NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service. NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service. GSK’s Nucala will now join Sanofi’s Dupixent within the NHS’s COPD biologic maintenance add-on treatment arsenal. Credit: M7Studio / Shutterstock.com. In another landmark for GSK’s blockbuster respiratory drug, Nucala (mepolizumab), the UK’s health watchdog has recommended the therapy’s use by the UK National Health Service (NHS) in patients with chronic obstructive pulmonary disease (COPD). In draft guidance debuted…

Source: Pharmaceutical Technology